...
首页> 外文期刊>Kobe journal of medical sciences >Characterization of Tamoxifen as an Antifungal Agent Using the Yeast Schizosaccharomyces Pombe Model Organism
【24h】

Characterization of Tamoxifen as an Antifungal Agent Using the Yeast Schizosaccharomyces Pombe Model Organism

机译:使用酵母裂殖酵母庞贝模型有机体表征他莫昔芬作为抗真菌剂。

获取原文
           

摘要

Tamoxifen, a selective estrogen receptor modulator used for managing breast cancer, is known to have antifungal activity. However, its molecular mechanism remains unknown. Using the fission yeast Schizosaccharomyces pombe as a model organism, we have explored the mechanism involved in antifungal action of tamoxifen. Since tamoxifen was shown to inhibit the binding of calmodulin to calcineurin in fungi, we first exa mined involvement of these molecules and found that o verexpression of a catalytic subunit of calcineurin and its constitutively active mutant as well as calmodulin increases tamoxifen sensitivity. Since terbinafine and azoles inhibit enzymes for ergosterol biosynthesis, Erg1 and Erg11, for their antifungal actions, we also exa mined involvement of these molecules. Overexpression of Erg1 and Erg11 reduced the sensitivity to terbinafine and azoles, respectively, but increased tamoxifen sensitivity, suggesting that ergosterol biosynthesis is differently related to the action of tamoxifen and those of terbinafine and azoles. To elucidate molecules involved in tamo xifen action, we performed a genome-wide screen for altered sensitivity to tamo xifen using a fission yeast gene deletion library, and identified various hypersensitive and resistant mutants to this drug. Notably, these mutants are rarely overlapped with those identified in similar genetic screens with currently used antifungals, suggesting a novel mode of antifungal action. Furthermore, ta moxifen augmented antifungal actions of terbinafine and a zoles, suggesting synergetic actions between these drugs. Therefore, our findings suggest that calmodulin-calcineurin pathway and ergosterol biosynthesis are related to antifungal action of tamoxifen, and propose novel targets for antifungal development as w ell as combined therapy with tamoxifen for fungal diseases.
机译:他莫昔芬是一种用于治疗乳腺癌的选择性雌激素受体调节剂,已知具有抗真菌活性。但是,其分子机制仍然未知。使用裂变酵母粟酒裂殖酵母作为模型生物,我们探索了他莫昔芬抗真菌作用的机制。由于显示他莫昔芬抑制真菌中钙调蛋白与钙调神经磷酸酶的结合,因此我们首先检查了这些分子的参与,发现钙调神经磷酸酶及其组成型活性突变体以及钙调蛋白的催化亚单位的正向表达增加了他莫昔芬的敏感性。由于特比萘芬和唑类抑制麦角固醇生物合成酶Erg1和Erg11的抗真菌作用,因此我们也检查了这些分子的参与。 Erg1和Erg11的过表达分别降低了对特比萘芬和唑的敏感性,但增加了他莫昔芬的敏感性,这表明麦角固醇的生物合成与他莫昔芬以及特比萘芬和唑的作用不同。为了阐明涉及他莫昔芬作用的分子,我们使用裂变酵母基因缺失文库对他莫昔芬对敏感性的改变进行了全基因组筛选,并鉴定了对该药物的各种超敏和抗性突变体。值得注意的是,这些突变体很少与使用当前使用的抗真菌剂在相似的基因筛选中鉴定出的那些突变体重叠,这表明了新型的抗真菌作用方式。此外,他莫昔芬增强了特比萘芬和唑类的抗真菌作用,表明这些药物之间具有协同作用。因此,我们的发现表明钙调蛋白-钙调神经磷酸途径和麦角甾醇的生物合成与他莫昔芬的抗真菌作用有关,并提出了与他莫昔芬联合治疗真菌疾病的抗真菌发展新靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号